secwatch.observer — SEC 8-K summary
======================================

Issuer:     ASSEMBLY BIOSCIENCES, INC. (ASMB)
CIK:        0001426800
Form:       8-K
Filed at:   2024-08-08T23:59:59+00:00
Accession:  0000950170-24-093946
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Assembly Biosciences Q2 2024 net loss $11.2M; cash runway into Q1 2026
----------------------------------------------------------------------

- Cash, equivalents and marketable securities $109.2M as of June 30, 2024, down from $113.0M at March 31, 2024.
- Revenue from Gilead collaboration $8.5M in Q2 2024 (vs. $0 in Q2 2023); R&D expenses $16.3M (up from $12.5M).
- Net loss $11.2M ($1.98 per share) vs. $16.9M ($3.88) in Q2 2023; net loss improved on higher revenue.
- Phase 1a/b dosing initiated for ABI-5366 (genital herpes) and Phase 1b for ABI-4334 (chronic HBV infection).
- Two additional candidates (ABI-1179, ABI-6250) expected to enter clinic by end of 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024093946/0000950170-24-093946-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1426800/000095017024093946/asmb-20240808.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-093946

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer